[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR900012625A - 시클로 스포린갈렌 제제 - Google Patents

시클로 스포린갈렌 제제 Download PDF

Info

Publication number
KR900012625A
KR900012625A KR1019900001492A KR900001492A KR900012625A KR 900012625 A KR900012625 A KR 900012625A KR 1019900001492 A KR1019900001492 A KR 1019900001492A KR 900001492 A KR900001492 A KR 900001492A KR 900012625 A KR900012625 A KR 900012625A
Authority
KR
South Korea
Prior art keywords
composition
component
components
present
pharmaceutical composition
Prior art date
Application number
KR1019900001492A
Other languages
English (en)
Other versions
KR0170769B1 (ko
Inventor
호이어 브시지트
포산스키 울리히
Original Assignee
장크라메르/한스루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898902898A external-priority patent/GB8902898D0/en
Priority claimed from GB898902901A external-priority patent/GB8902901D0/en
Priority claimed from GB898903147A external-priority patent/GB8903147D0/en
Priority claimed from GB898903663A external-priority patent/GB8903663D0/en
Application filed by 장크라메르/한스루돌프 하우스, 산도즈 리미티드 filed Critical 장크라메르/한스루돌프 하우스
Publication of KR900012625A publication Critical patent/KR900012625A/ko
Application granted granted Critical
Publication of KR0170769B1 publication Critical patent/KR0170769B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

시클로 스포린갈렌 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. a)활성성분으로 시클로스포린, b) 지방산당 모노에스테르, 및 c) 희석제 또는 담체를 함유하고, I) 성분(c)는 두성분 (a)와 (b)에 대한 용제이고 성분 (a)와 (b)는 각각 독립적으로 주위온도에서 성분 (c)에 대해 최소한 10%의 용해도를 갖고 : 또는 ii) 성분 (c)는 두성분 (a)와 (b)에 대한 용제이고 성분 (a)와 (c)는 상기 조성물내에 1 ; 0.5-50p.p.w[(a) :(c)]의 비율로 존재하고 : 또는 iii) 성분 (c)는 두성분 (a)와 (b)에 대한 용제이고 상기 조성물은 경구투여에 적합한 고형 단위 복용 형태로 제조되며 : 또는 iv) 성분 (c)는 평균 분자량이 최고 7,000이며 주위 온도에서 점성도가 최고 15,000Pa.s인 폴리-(C2-4알킬렌)-글리콜을 포함하거나 C3-5알킬렌 폴리올에테르 또는 에스테르를 포함하고 : 또는 v) 상기 조성물은 비-수용성이거나 거의 비-수용성이고 : 또는 vi) 성분(c)는 고형 중합성 담체, 유기 실리콘 산화물 중합체 또는 액상 또는 액하 파라핀을 포함하고 성분 (a)는 상기 조성물내에 (b)의 고형액으로 존재하는 약학 조성물.
  2. a) 활성성분으로 시클로스포린, b) 지방산 당 모노에스테르, 및 c) c1) 에탄올, c2), C2-4알킬렌 글리콜 c3) C3-5알킬렌 폴리올, c4) 폴리-(C2-4알킬렌) 글리콜 및 그들의 혼합물로 구성된 군으로부터 선택된 희석제를 함유하고, ii) 성분 (a)와 (c)가 상기조성물에 1 : 0.5-50p.p.w[(a) :(c)]의 비율로 존재하고 : 또는 iii) 상기 조성물은 경구 투여에 적합한 고형 단위 복용 형태로 제조되며 : 또는 iv) 성분(c)는 평균 분자량이 최고 7,000이거나 50℃에서 점성도가 최고 15,000mpa.s.인 성분 (c4)를 포함하고 : 또는 v) 상기 조성물은 비수용성이거나 거의 비수용성인 약학 조성물.
  3. a) 활성성분으로 시클로스포린, b) 지방산 당 모노에스테르, 및 c2) 1,2-프로필렌 글리콜을 함유하고 ii) 성분 (a)와 (c2)가 상기 조성물에서 1 : 0.5-50p.p.w[(1) :(c2)]의 비율로 존재하고 : 또는 iii) 상기 조성물 경구투여에 적합한 고형 단위 복용 형태로 제조되고 : 또는 v) 상기 조성물은 비수용성이거나 거의 비수용성인 약학 조성물.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, 성분 (a)와 (b)가 1 : 30-200p.p.w[(a) :(b)]의 비율로 존재하는 약학 조성물.
  5. a) 고형액 상태로 활성 성분인 시클로 스포린 : b) 지방산 당 모노에스테르 : 및 c6) 폴리비닐피롤리돈을 포함하는 고형 중합성 담체를 포함하는 약학 조성물.
  6. 제5항에 있어서, 성분 (a)와 (b)는 1 : 2-20p.p.w[(a) : (b)]의 비율로 존재하고 성분(c6)는 조성물의 총중량에 대해 최소한 10중량%의 양으로 존재하는 약학 조성물.
  7. 제1항 내지 제6항중 어느 한 항에 있어서, 단위 복용단 2-200mg의 성분(a)를 포함하는 단위 복용 형태의 약학 조성물.
  8. a) 활성성분으로 시클로스포린, b) 지방산 당 모노에스테르, 및 c2) 1,2-프로필렌 글리콜을 함유하고, 상기 조성물은 단위 복용 형태이며 단위 복용단 약 20-100mg의 성분(a)를 포함하고 성분(a)와 (b)는 상기조성물에 1 : -200p.p.w[(a) : (c)]의 비율로 존재하며 성분(a)와 (c)는 상기 조성물에 1 : 0.5-500p.p.w[(a) : (c)]의 비율로 존재하는 약학 조성물.
  9. 제1항 내지 제8항중 어느 한 항에 있어서, 성분 (a)가 Ciclosporin 또는 [Nva]2-Ciclosporin인 약학 조성물.
  10. 제1항 내지 제9항중 어느 한 항에 있어서, 성분(b)가 라피노즈 또는 사카로즈 모노라우레이트를 포함하는 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900001492A 1989-02-09 1990-02-08 신규한 사이클로스포린 갈렌 제제 KR0170769B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB898902898A GB8902898D0 (en) 1989-02-09 1989-02-09 Improvements in or relating to organic compounds
GB898902901A GB8902901D0 (en) 1989-02-09 1989-02-09 Improvements in or relating to organic compounds
GB8902901 1989-02-09
GB8902898 1989-02-09
GB8903147 1989-02-13
GB898903147A GB8903147D0 (en) 1989-02-13 1989-02-13 Improvements in or relating to organic compounds
GB898903663A GB8903663D0 (en) 1989-02-17 1989-02-17 Improvements in or relating to organic compounds
GB8903663 1989-02-17

Publications (2)

Publication Number Publication Date
KR900012625A true KR900012625A (ko) 1990-09-01
KR0170769B1 KR0170769B1 (ko) 1999-02-01

Family

ID=27450262

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900001492A KR0170769B1 (ko) 1989-02-09 1990-02-08 신규한 사이클로스포린 갈렌 제제

Country Status (25)

Country Link
JP (3) JP3484190B2 (ko)
KR (1) KR0170769B1 (ko)
AT (1) AT404552B (ko)
AU (1) AU630413B2 (ko)
BE (1) BE1003009A5 (ko)
CA (1) CA2009533C (ko)
CH (1) CH679277A5 (ko)
CY (1) CY1903A (ko)
DE (1) DE4003844B4 (ko)
DK (1) DK176209B1 (ko)
ES (1) ES2021942A6 (ko)
FI (1) FI97524C (ko)
FR (1) FR2642650B1 (ko)
GB (1) GB2230440B (ko)
HK (1) HK37296A (ko)
HU (1) HU213394B (ko)
IT (1) IT1240758B (ko)
LU (1) LU87675A1 (ko)
MY (1) MY107377A (ko)
NL (1) NL195028C (ko)
NO (1) NO301576B1 (ko)
NZ (1) NZ232401A (ko)
PH (1) PH30917A (ko)
PT (1) PT93079B (ko)
SE (1) SE511398C2 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190119936A (ko) 2018-04-13 2019-10-23 가천대학교 산학협력단 사이클로스포린 A (CsA) 경피 및 피내 약물전달용 마이크로구조체

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
MX9201782A (es) † 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
EP0642332B1 (en) 1992-05-13 1997-01-15 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
US5759566A (en) * 1992-07-28 1998-06-02 Poli Industria Chimica Spa Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents
EP1142568A1 (en) 1992-09-25 2001-10-10 Novartis AG Pharmaceutical compositions containing cyclosporins
SK283442B6 (sk) † 1993-04-20 2003-07-01 Novartis Ag Farmaceutický prípravok na orálne podanie
DE4412201A1 (de) * 1993-04-20 1994-11-10 Rentschler Arzneimittel Neue pharmazeutische Zubereitungen zur oralen Verabreichung enthaltend Cyclosporin
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
RU2158601C2 (ru) 1994-11-03 2000-11-10 Новартис Аг Новые лекарственные формы циклоспорина для орального применения с простым составом и высокой биодоступностью и способ их получения
US5679566A (en) * 1995-01-20 1997-10-21 University Of Massachusetts Medical Center Yeast NMD2 gene
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
DE19549852B4 (de) 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
US5798333A (en) * 1996-09-17 1998-08-25 Sherman; Bernard C. Water-soluble concentrates containing cyclosporins
BR9807528A (pt) 1997-01-30 2000-03-14 Novartis Ag Composições farmacêuticas isentas de óleo contendo ciclosporina a
AU762247B2 (en) * 1997-01-30 2003-06-19 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
SI0969856T1 (en) * 1997-03-12 2005-06-30 Abbott Laboratories Hydrophilic binary systems for the administration of cyclosporine
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
JP4521554B2 (ja) * 2004-03-31 2010-08-11 マイラン製薬株式会社 シクロスポリン製剤
CN101360485B (zh) * 2005-10-26 2013-04-17 班纳制药公司 作为胶囊填充物的基于亲水性载体的双重控释基质系统
EP2004203A4 (en) * 2006-03-28 2010-03-31 Javelin Pharmaceuticals Inc FORMULATIONS OF DICLOFENAC AND CYCLODEXTRIN BETA WITH LOW DOSAGE
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102008059201A1 (de) * 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
WO2023063376A1 (ja) * 2021-10-13 2023-04-20 中外製薬株式会社 ペプチド化合物及び界面活性剤を含む組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
JPS61280435A (ja) * 1985-04-04 1986-12-11 Kanji Takada サイクロスポリン類のリンパ指向性製剤
NL8600050A (nl) * 1986-01-13 1987-08-03 Sanico Nv Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.
GB8602372D0 (en) * 1986-01-31 1986-03-05 Sandoz Ltd Organic compounds
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
AU617295B2 (en) * 1986-11-13 1991-11-28 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
ATE95193T1 (de) * 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
JP2536876B2 (ja) * 1987-07-31 1996-09-25 寛治 高田 シクロスポリンの溶解性粉末状製剤
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
DE3830494B4 (de) * 1987-09-15 2006-05-18 Novartis Ag Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe
HU205010B (en) * 1987-09-15 1992-03-30 Sandoz Ag Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
JP2792862B2 (ja) * 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
JPH1038029A (ja) * 1996-07-26 1998-02-13 Ebara Corp 制振機能付き円板状構造物
JPH10280435A (ja) * 1997-04-03 1998-10-20 Sekisui Chem Co Ltd 地下室の構築方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190119936A (ko) 2018-04-13 2019-10-23 가천대학교 산학협력단 사이클로스포린 A (CsA) 경피 및 피내 약물전달용 마이크로구조체

Also Published As

Publication number Publication date
JP4073641B2 (ja) 2008-04-09
PH30917A (en) 1997-12-23
FR2642650A1 (fr) 1990-08-10
DK32790A (da) 1990-08-10
FI97524C (fi) 1997-01-10
CH679277A5 (ko) 1992-01-31
GB2230440B (en) 1993-05-19
JPH02235817A (ja) 1990-09-18
FR2642650B1 (fr) 1994-12-09
FI900604A0 (fi) 1990-02-07
JP2006001947A (ja) 2006-01-05
IT9047609A1 (it) 1991-08-08
SE9000441L (sv) 1991-08-08
HU213394B (en) 1997-06-30
GB2230440A (en) 1990-10-24
AU4925290A (en) 1990-08-16
DK32790D0 (da) 1990-02-07
JP3484190B2 (ja) 2004-01-06
CY1903A (en) 1996-11-22
SE511398C2 (sv) 1999-09-20
AU630413B2 (en) 1992-10-29
NL195028C (nl) 2003-12-02
SE9000441D0 (sv) 1990-02-07
NO900577D0 (no) 1990-02-07
CA2009533C (en) 2002-11-12
NO301576B1 (no) 1997-11-17
IT9047609A0 (it) 1990-02-08
GB9002504D0 (en) 1990-04-04
DK176209B1 (da) 2007-02-05
NL9000299A (nl) 1990-09-03
NZ232401A (en) 1992-10-28
AT404552B (de) 1998-12-28
LU87675A1 (fr) 1991-10-08
HK37296A (en) 1996-03-15
BE1003009A5 (fr) 1991-10-22
FI97524B (fi) 1996-09-30
JP2001302538A (ja) 2001-10-31
ES2021942A6 (es) 1991-11-16
IT1240758B (it) 1993-12-17
HU900701D0 (en) 1990-04-28
NO900577L (no) 1990-08-10
NL195028B (nl) 2003-08-01
CA2009533A1 (en) 1990-08-09
MY107377A (en) 1995-11-30
DE4003844B4 (de) 2007-09-20
PT93079B (pt) 1996-04-30
ATA27290A (de) 1998-05-15
PT93079A (pt) 1990-08-31
DE4003844A1 (de) 1990-08-16
KR0170769B1 (ko) 1999-02-01

Similar Documents

Publication Publication Date Title
KR900012625A (ko) 시클로 스포린갈렌 제제
CA2494762C (en) Pharmaceutical compositions comprising cyclosporin for oral administration
JP2001525363A5 (ko)
KR890001521A (ko) 서방형 신규 제약 제제물
MY109512A (en) Pharmaceutical composition
KR970064620A (ko) 사이클로스포린-함유 외용약제 조성물
RU99113343A (ru) Лекарственные формы циклоспорина для перорального введения
KR20000069688A (ko) 경구투여용 시클로스포린 제형
EP1109532A1 (en) Oral micro-emulsion composition of silybin
RU2002135623A (ru) Рецептура на основе гепарина, глюкозаминогликана или гепариноида и применение рецептуры и ее основы
CA2494796C (en) Pharmaceutical formulation comprising cyclosporin, propylene glycol ester and non-ionic surfactant
JP2002537242A5 (ko)
US20030180350A1 (en) Combination compositions
EP1572241B1 (en) Oral pharmaceutical compositions comprising cyclosporin
KR950007857A (ko) 경구투여용 라파마이신 제제
CZ291237B6 (cs) Farmaceutický přípravek pro orální podání obsahující cyklosporin A
CA1112572A (en) Injectable chloramphenicol composition
ZA200104828B (en) Cyclosporin solution.
JP2003055254A (ja) 経口投与用シクロスポリン製剤
IL93298A (en) Pharmaceutical compositions comprising cyclosporin
CN1104258C (zh) 用于环孢霉素a的赋形剂
KR950026527A (ko) 사이클로스포린-함유 약제학적 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120924

Year of fee payment: 15

EXPY Expiration of term